Outcomes of initial therapy for synchronous brain metastases from small cell lung cancer: a single-institution retrospective analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.For small cell lung cancer (SCLC) patients with brain metastases, combining chemotherapy and whole brain radiation therapy (WBRT) improves survival. Upfront surgery also aids overall survival in these SCLC patients.
Area Of Science
- Oncology
- Neurology
- Radiotherapy
Background
- Small cell lung cancer (SCLC) frequently metastasizes to the brain, significantly worsening patient prognosis.
- Synchronous brain metastases at diagnosis present a critical challenge in SCLC management.
Purpose Of The Study
- To identify predictors of overall survival (OS) and brain progression-free survival (bPFS) in SCLC patients diagnosed with synchronous brain metastases.
- To evaluate the impact of different treatment modalities on survival outcomes in this patient cohort.
Main Methods
- Retrospective analysis of 107 SCLC patients with synchronous brain metastases.
- Kaplan-Meier survival estimates and Cox proportional hazards regression were used for analysis.
- Comparison of outcomes based on treatment combinations (chemotherapy, WBRT, surgery) and disease characteristics.
Main Results
- Median OS was 9 months and median bPFS was 7.3 months.
- An increased number of brain lesions correlated with decreased OS.
- Combined chemotherapy and WBRT significantly improved both OS and bPFS compared to single modalities.
- Upfront brain metastasis resection was associated with improved OS but not bPFS.
Conclusions
- The combination of chemotherapy and WBRT is a superior treatment strategy for SCLC patients with synchronous brain metastases.
- While upfront surgery may improve overall survival, its impact on brain progression requires further investigation.
- Identifying prognostic factors is crucial for optimizing treatment and improving outcomes in SCLC brain metastases.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
